Antibody Therapeutics Patients First!

공지사항

PharmAbcine is invited and will attend to the 35th Annual J.P. Morgan Healthcare Conference.
  • 글쓴이 관리자
  • 작성일 2018-08-06 11:31:23
  • 조회수 816

PharmAbcine is invited and will attend to the 35th Annual J.P. Morgan Healthcare Conference

 

Daejeon, South Korea., Jan. 06, 2017 -- PharmAbcine, a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Jin-San Yoo., Ph.D., President and Chief Executive Officer, will attend to the 35th Annual J.P. Morgan Healthcare Conference and present PharmAbcine’s R&D progress at the prearranged meetings with partners.

 

 

 

About PharmAbcine

PharmAbcine, Inc. discovers and develops innovative bio-therapeutics to improve the quality of patients’ life with devastating diseases like cancer 

and auto immune diseases. PharmAbcine`s competitive fully human antibody libraries, target customized selection system for druggable candidate,

innovative multispecific antibody platforms, patients derived cancer stem cell collections under the collaboration with Samsung medical Center 

and its animal model systemto validate drug candidates, innovative pipeline and established 3G System to generate high performing cell line system

will position PharmAbcine as a leading immuno-oncology company.

 

The ongoing strategic collaborations with leading both global and domestic pharmaceutical companies look promising product candidates 

in clinical and nonclinical development stage.

 

For more information, please visit www.pharmabcine.com.

 

CONTACT:

 

Dr. Sung Woo Kim, Investor Relations

 

+82-42-863-2017

 

sungwoo.kim@pharmabcine.com

목록





이전글 이전글이 없습니다.
다음글 Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present at ``3rd Biologics and...